KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $45.3 million.

  • Alnylam Pharmaceuticals' Cash from Financing Activities rose 4619.8% to $45.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$305.2 million, marking a year-over-year decrease of 20375.0%. This contributed to the annual value of -$305.2 million for FY2025, which is 20375.0% down from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Cash from Financing Activities of $45.3 million as of Q4 2025, which was up 4619.8% from -$448.3 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Cash from Financing Activities high stood at $573.8 million for Q3 2021, and its period low was -$448.3 million during Q3 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Cash from Financing Activities value was $48.8 million (recorded in 2021), while the average stood at $91.7 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 158049.61% in 2021, then tumbled by 53632.72% in 2025.
  • Alnylam Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $292.3 million in 2021, then tumbled by 78.3% to $63.4 million in 2022, then tumbled by 38.16% to $39.2 million in 2023, then fell by 20.98% to $31.0 million in 2024, then soared by 46.2% to $45.3 million in 2025.
  • Its Cash from Financing Activities was $45.3 million in Q4 2025, compared to -$448.3 million in Q3 2025 and $53.8 million in Q2 2025.